Within the limitations of this study, the systemic administration of melatonin has been successfully used for decreasing bone destruction in a rat model of osteoporosis and periodontitis by inhibiting both osteoclasts and the RANKL expression. The gene discussed is TNFSF11; the disease is osteoporosis.